Please note locations: General GI clinic Tuesday mornings on Yawkey 6; Neurogastroenterology clinic Wednesday mornings on Warren 11; pediatric endoscopy suite Tuesday and Wednesday afternoons and some Fridays on Gray 4.
BiographyAs director of the multidisciplinary Neurogastroenterology Program at MassGeneral Hospital for Children (MGHfC), Jaime-Belkind Gerson, MD, MSc, evaluates hospitalized and ambulatory pediatric patients with chronic intestinal neurological disorders. Dr. Belkind-Gerson focuses on motility (motion and function through the GI tract) and sensory diseases of the gastrointestinal tract, including irritable bowel syndrome, functional disorders, congenital malformations, intestinal pseudo-obstruction, intractable constipation, Hirschsprung's disease and other conditions.
Dr. Belkind-Gerson is also director of the pediatric gastrointestinal motility laboratory. The lab's goal is to bring the best in testing from the adult motility field into effective testing for children, including a wireless motility capsule and advanced manometry procedures (during manometry a thin, pressure-sensitive tube is inserted through your nose down through the esophagus into the stomach).
As an MGHfC fellow and junior faculty, Dr. Belkind-Gerson was part of the research lab that identified ENS-derived neural stem cells in the gut, leading to new therapeutic possibilities. Dr. Belkind-Gerson received his medical degree from the Universidad Nacional Autonoma de Mexico in 1989 and returned to his native country for eight years to found a pediatric gastroenterology department in a hospital in a severely underserved area of south-central Mexico before returning to MassGeneral in 2010.
ResearchDr. Belkind-Gerson heads the Pediatric Motility Laboratory. HIS research is focused on the postnatal development of the Enteric Nervous System (ENS) (the nervous system of the gut) and its regeneration. As an MGHfC fellow and junior faculty, Dr. Belkind-Gerson was part of the research lab that identified ENS-derived neural stem cells in the gut, leading to new therapeutic possibilities.
The ultimate goal of his research program is to build on the findings on intestinal NSCs, define their potential role in health and disease and design cell-based therapies for neurointestinal pathology. His goal is to contribute in improving the treatment of severely incapacitating intestinal motility and sensory disorders such as Hirschsprung's disease and Gastroparesis.
Dr. Belkind-Gerson also works on clinical and translationa research by collaborating with the adult GI motility program as well as other disciplines such as psychiatry and neurology in multiple clinical research protocols, both at MGH and external centers. These studies are aimed at evaluating new diagnostic technologies in motility such as the wireless motility capsule and high-resolution manometry as well new therapeutic options including novel pro-motility drugs and neuro-mediators.
Isolation, Characterization and Transplant of intestinal-Derived Neural Stem Cells as a Treatment for Intestinal Neuropathies
Recent news reports have brought about concern over PEG3350, a common ingredient in laxatives used to relieve constipation in children. Jaime Belkind-Gerson, MD, medical director of Pediatric Neurogastroenterology and Nutrition, answers common questions about PEG3350, its safety and its use in children.
You can see MassGeneral for Children specialists in more than a dozen locations throughout Eastern Massachusetts and Southern New Hampshire.
Contact MassGeneral Hospital for Children to schedule an appointment with one of our specialists.
Referring a patient to MassGeneral Hospital for Children is easy.